Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action

Area of Science:

• Critical Care Medicine
• Pharmacology
• Infectious Diseases

Background:

• Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
• Platelet activation and aggregation play a significant role in sepsis-induced microvascular thrombosis and organ damage.
• Current sepsis guidelines do not specifically recommend antiplatelet agents.

Purpose of the Study:

• To synthesize current evidence on the use of antiplatelet agents in sepsis.
• To highlight the potential benefits and risks of antiplatelet therapy in sepsis.
• To call for further research and clinical trials.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the pathophysiological mechanisms linking platelets and sepsis.
• Discussion of existing clinical trial data and expert opinions.

Main Results:

• Preclinical studies suggest antiplatelet agents may reduce thrombosis and improve outcomes in sepsis models.
• Clinical data on antiplatelet use in sepsis is limited and often conflicting.
• Potential benefits include improved microcirculation and reduced organ damage, while risks include increased bleeding.

Conclusions:

• Antiplatelet agents represent a potential therapeutic strategy in sepsis, but robust clinical evidence is lacking.
• Further well-designed clinical trials are essential to determine the efficacy, safety, and optimal patient population for antiplatelet therapy in sepsis.
• A call to action for researchers and clinicians to investigate this therapeutic avenue.